Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer
Custodio AB et al. - Patients with early stage NSCLC are at substantial risk for recurrence even after potentially curative surgical resection, and adjuvant chemotherapy. The current staging system is inadequate for predicting the outcome of treatment and the prognosis in an individual patient. Molecular markers may provide additional information about the likelihood of relapse beyond that obtained from pathologic staging. They may also have value in determining which patients will benefit from adjuvant platinum-based chemotherapy. This review focuses on: - Approaches and specific markers under study
- Gene expression profiles
- DNA repair pathways
- Class III β-tubulin expression
- Abnormalities in the k-ras oncogene and p53 tumor suppressor gene, and
- DNA methylation markers
Additional studies will be required to determine whether these markers are useful in selecting pts for adjuvant platinum based chemotherapy [more...]
|
|
|
